Sulfadiazine silver
Silvadene, Ssd, Thermazene (sulfadiazine, silver) is a small molecule pharmaceutical. Sulfadiazine, silver was first approved as Silvadene on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burns | D002056 | — | T30.0 | — | 5 | 4 | 5 | 10 | 23 |
| Hearing loss | D034381 | EFO_0004238 | H91.9 | — | — | — | 1 | 12 | 13 |
| Deafness | D003638 | EFO_0001063 | H91.9 | — | — | — | 1 | 12 | 13 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 2 | — | 1 | 4 | 7 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | — | 1 | — | 3 |
| Communicable diseases | D003141 | — | — | 1 | 2 | — | 1 | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | 1 | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | 1 | — | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | 1 | — | 1 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic encephalopathy | D006501 | — | K72.91 | — | 1 | 2 | — | — | 3 |
| Brain diseases | D001927 | — | G93.40 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Somatoform disorders | D013001 | — | F45 | — | 1 | — | — | 4 | 5 |
| Radiodermatitis | D011855 | — | L58 | — | 2 | — | — | 2 | 4 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | 1 | 2 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | — | 1 | 2 |
| Dermatitis | D003872 | — | L30.9 | — | 2 | — | — | — | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | 1 | 2 |
| Uterine cervical neoplasms | D002583 | — | — | — | 1 | — | — | 1 | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 1 | 2 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | 1 | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
| Hepatitis | D006505 | — | K75.9 | 1 | — | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Unilateral hearing loss | D046088 | — | — | — | — | — | — | 7 | 7 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | — | 5 | 5 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 5 | 5 |
| Speech sound disorder | D066229 | — | — | — | — | — | — | 3 | 3 |
| Conductive hearing loss | D006314 | — | H90.2 | — | — | — | — | 3 | 3 |
| Medically unexplained symptoms | D000071896 | — | — | — | — | — | — | 3 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 3 | 3 |
| Mixed conductive-sensorineural hearing loss | D046089 | — | H90.8 | — | — | — | — | 2 | 2 |
| Fibrosis | D005355 | — | — | — | — | — | — | 2 | 2 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 2 | 2 |
Show 51 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sulfadiazine silver |
| INN | — |
| Description | Silver(1+) sulfadiazinate is a silver salt, a sulfonamidate and a member of pyrimidines. It has a role as an antimicrobial agent and an antibacterial drug. It contains a sulfadiazinate. |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+] |
Identifiers
| PDB | — |
| CAS-ID | 22199-08-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1382627 |
| ChEBI ID | 9142 |
| PubChem CID | 441244 |
| DrugBank | DB05245 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Sulfadiazine silver
+
Silver sulfadiazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
907 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use